BBVA USA’s Ingevity NGVT Stock Holding History

BBVA USA’s Portfolio NGVT Stock Details NGVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$1K	Hold	16	–	–	﹤0.01%	956
2021 Q2	$1K	Buy	+16	New	+$1.29K	﹤0.01%	994

Other funds holding NGVT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

BBCM

Broad Bay Capital Management New York $1.18B AUM 65.45% 1-Year Est. Return

ICP

Inclusive Capital Partners San Francisco, California $26M AUM 22.24% 1-Year Est. Return

AAM

Ardevora Asset Management London, United Kingdom $1.12B AUM 26.09% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BBVA USA's NGVT Position: Q3 2021 in Review

BBVA USA held its Ingevity (NGVT) position steady in Q3 2021 at 16 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #956.

BBVA USA first reported a position in NGVT in Q2 2021 and has held it in 2 quarters since. 277 funds tracked by Wall St. Rank hold NGVT as of Q3 2021.

BBVA USA held 16 shares of Ingevity worth $1K as of Q3 2021.
BBVA USA left its Ingevity share count unchanged in Q3 2021.
Ingevity made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #956 holding.
BBVA USA first reported a position in Ingevity in Q2 2021 and has held it in 2 quarters since.
277 funds tracked by Wall St. Rank held Ingevity as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.